|
WO2013154760A1
(en)
|
2012-04-11 |
2013-10-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting b-cell maturation antigen
|
|
US20150320799A1
(en)
|
2012-12-20 |
2015-11-12 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
PL2953972T3
(pl)
|
2013-02-05 |
2021-03-08 |
Engmab Sàrl |
Metoda wyboru przeciwciał przeciwko bcma
|
|
KR20150131218A
(ko)
|
2013-03-14 |
2015-11-24 |
벨리쿰 파마슈티컬스, 인크. |
T 세포 증식의 제어 방법
|
|
KR102238226B1
(ko)
|
2013-05-14 |
2021-04-09 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
가공된 키메라 항원 수용체 (car) t-세포의 인간 적용
|
|
GB201317929D0
(en)
*
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
JP2016537345A
(ja)
|
2013-11-13 |
2016-12-01 |
ノバルティス アーゲー |
免疫応答を増強するためのmTOR阻害剤
|
|
ES2792849T3
(es)
|
2014-02-10 |
2020-11-12 |
Univ Emory |
Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer
|
|
CN106132423B
(zh)
|
2014-02-14 |
2020-07-31 |
贝里坤制药股份有限公司 |
用诱导型嵌合多肽活化t细胞的方法
|
|
KR102375998B1
(ko)
|
2014-02-14 |
2022-03-21 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
키메라 항원 수용체 및 제조방법
|
|
EP3243831A1
(en)
|
2014-02-27 |
2017-11-15 |
Ucl Business Plc |
Variants of the proliferation-inducing ligand (april)
|
|
ES2740903T3
(es)
*
|
2014-03-19 |
2020-02-07 |
Cellectis |
Receptores antigénicos quiméricos específicos de CD123 para inmunoterapia del cáncer
|
|
SG11201608393TA
(en)
*
|
2014-04-10 |
2016-11-29 |
Seattle Children S Hospital Dba Seattle Children S Res Inst |
Transgene genetic tags and methods of use
|
|
EP3131927B8
(en)
|
2014-04-14 |
2020-12-23 |
Cellectis |
Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
|
|
EP3738597A1
(en)
*
|
2014-04-25 |
2020-11-18 |
Bluebird Bio, Inc. |
Improved methods for manufacturing adoptive cell therapies
|
|
SI3689899T1
(sl)
|
2014-04-25 |
2022-01-31 |
2Seventy Bio, Inc. |
MND promotor kimeričnih antigenskih receptorjev
|
|
EP4008725A1
(en)
|
2014-05-02 |
2022-06-08 |
The Trustees of the University of Pennsylvania |
Compositions and methods of chimeric autoantibody receptor t cells
|
|
AU2015270912B9
(en)
*
|
2014-06-02 |
2021-01-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting CD-19
|
|
NZ726989A
(en)
*
|
2014-06-06 |
2020-08-28 |
Bluebird Bio Inc |
Improved t cell compositions
|
|
ES2813437T3
(es)
|
2014-07-11 |
2021-03-23 |
Celgene Corp |
Métodos para mejorar la eficiencia de la transducción vectorial en linfocitos T
|
|
MX2017000646A
(es)
|
2014-07-15 |
2017-04-27 |
Juno Therapeutics Inc |
Celulas geneticamente modificadas para terapia celular adoptiva.
|
|
CN107109420A
(zh)
|
2014-07-21 |
2017-08-29 |
诺华股份有限公司 |
使用cll-1嵌合抗原受体的癌症治疗
|
|
WO2016014565A2
(en)
*
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
|
SG10201900455YA
(en)
*
|
2014-07-24 |
2019-02-27 |
Bluebird Bio Inc |
Bcma chimeric antigen receptors
|
|
BR112017001821A2
(pt)
*
|
2014-07-29 |
2017-11-21 |
Cellectis |
receptores de antígenos quiméricos específicos de ror1 (ntrkr1) para imunoterapia de câncer
|
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
JP6868554B2
(ja)
|
2014-09-02 |
2021-05-12 |
ベリカム ファーマシューティカルズ, インコーポレイテッド |
MyD88およびCD40ポリペプチドによるキメラ抗原受容体の共刺激
|
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
|
SG10201900931XA
(en)
*
|
2014-12-05 |
2019-02-27 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
|
DK3226897T3
(da)
|
2014-12-05 |
2021-04-19 |
Memorial Sloan Kettering Cancer Center |
Antistoffer der rammer b-cellemodningsantigen og fremgangsmåder til anvendelse
|
|
NZ733025A
(en)
*
|
2014-12-12 |
2022-01-28 |
2Seventy Bio Inc |
Bcma chimeric antigen receptors
|
|
KR20170090506A
(ko)
*
|
2014-12-19 |
2017-08-07 |
다나-파버 캔서 인스티튜트 인크. |
키메라 항원 수용체 및 이의 사용 방법
|
|
HRP20191400T1
(hr)
|
2014-12-24 |
2019-11-15 |
Aadigen Llc |
Peptidi i nanočestice za unutarstaničnu isporuku molekula
|
|
CA2973529A1
(en)
|
2015-01-26 |
2016-08-04 |
Cellectis |
Cll1-specific multi-chain chimeric antigen receptor
|
|
CN107614008A
(zh)
*
|
2015-03-20 |
2018-01-19 |
蓝鸟生物公司 |
载体制剂
|
|
EP3273994B1
(en)
|
2015-03-27 |
2021-12-01 |
University of Southern California |
Car t-cell therapy directed to lhr for the treatment of solid tumors
|
|
JP6921001B2
(ja)
*
|
2015-04-13 |
2021-08-18 |
ファイザー・インク |
B細胞成熟抗原を標的にするキメラ抗原受容体
|
|
ES3012402T3
(en)
|
2015-04-13 |
2025-04-09 |
Pfizer |
Therapeutic antibodies and their uses
|
|
CN108136021A
(zh)
|
2015-04-25 |
2018-06-08 |
综合医院公司 |
用于治疗癌症的抗驱走性试剂和抗癌剂联合疗法和组合物
|
|
GB201507119D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
|
KR20180029201A
(ko)
|
2015-05-18 |
2018-03-20 |
티씨알2 테라퓨틱스 인크. |
융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법
|
|
CN107847491A
(zh)
|
2015-05-20 |
2018-03-27 |
诺华公司 |
依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
|
|
CN107847601A
(zh)
*
|
2015-06-04 |
2018-03-27 |
南加利福尼亚大学 |
Lym‑1和lym‑2靶向的car细胞免疫疗法
|
|
CN107708741A
(zh)
*
|
2015-06-12 |
2018-02-16 |
免疫医疗公司 |
用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法
|
|
PT3310805T
(pt)
|
2015-06-19 |
2021-05-19 |
Kobold Sebastian |
Proteínas de fusão pd-1-cd28 e a sua utilização em medicina
|
|
MA42895A
(fr)
*
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
PT3331910T
(pt)
|
2015-08-03 |
2020-03-24 |
Engmab Sarl |
Anticorpos monoclonais contra o antigénio de maturação de células b (bcma) humano
|
|
US11458167B2
(en)
|
2015-08-07 |
2022-10-04 |
Seattle Children's Hospital |
Bispecific CAR T-cells for solid tumor targeting
|
|
CN105384825B
(zh)
*
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
JP7010487B2
(ja)
|
2015-08-17 |
2022-03-03 |
ソウル大学校産学協力団 |
抗コチニン抗体が連結したキメラ抗原受容体およびその使用
|
|
EP3349797A4
(en)
|
2015-09-18 |
2019-06-12 |
The General Hospital Corporation Dba Massachusetts General Hospital |
LOCALIZED RELEASE OF ANTIFUGETACTIC AGENT FOR THE TREATMENT OF CANCER
|
|
ES2895901T3
(es)
|
2015-10-16 |
2022-02-23 |
Univ Muenchen Ludwig Maximilians |
Células T transducidas con CXCR6 para terapia tumoral dirigida
|
|
WO2017070042A1
(en)
|
2015-10-20 |
2017-04-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing t cell populations using akt inhibitors
|
|
US10925969B2
(en)
|
2015-11-13 |
2021-02-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Service |
Anti-BCMA polypeptides and proteins
|
|
US20190153049A1
(en)
*
|
2015-11-26 |
2019-05-23 |
Guangzhou Cas Lamvac Biotech Co., Ltd. |
Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof
|
|
WO2017088012A1
(en)
|
2015-11-27 |
2017-06-01 |
Cartherics Pty. Ltd. |
Genetically modified cells and uses thereof
|
|
US11479755B2
(en)
|
2015-12-07 |
2022-10-25 |
2Seventy Bio, Inc. |
T cell compositions
|
|
EP3184548A1
(en)
*
|
2015-12-23 |
2017-06-28 |
Miltenyi Biotec GmbH |
Chimeric antigen receptor with cytokine receptor activating or blocking domain
|
|
US11571469B2
(en)
|
2016-01-07 |
2023-02-07 |
Mayo Foundation For Medical Education And Research |
Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
|
|
EP3408297A2
(en)
|
2016-01-29 |
2018-12-05 |
Med Manor Organics, (P) Ltd |
A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
|
|
WO2017139199A1
(en)
|
2016-02-10 |
2017-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Inducible arginase
|
|
PL3436079T3
(pl)
|
2016-04-01 |
2021-12-20 |
Kite Pharma, Inc. |
Antygen chimeryczny i receptory komórek t oraz sposoby ich stosowania
|
|
PE20190356A1
(es)
|
2016-04-01 |
2019-03-07 |
Kite Pharma Inc |
Receptores quimericos y metodos de uso de los mismos
|
|
US10689450B2
(en)
*
|
2016-04-01 |
2020-06-23 |
Kite Pharma, Inc |
BCMA binding molecules and methods of use thereof
|
|
JP7282521B2
(ja)
|
2016-04-08 |
2023-05-29 |
パーデュー・リサーチ・ファウンデイション |
Car t細胞療法のための方法および組成物
|
|
AU2017271606B2
(en)
|
2016-05-27 |
2024-08-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
FLT3-specific chimeric antigen receptors and methods using same
|
|
US12048718B2
(en)
|
2016-06-07 |
2024-07-30 |
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft |
Chimeric antigen receptor and CAR-T cells that bind BCMA
|
|
EP3478722A1
(en)
|
2016-06-30 |
2019-05-08 |
F. Hoffmann-La Roche AG |
Improved adoptive t-cell therapy
|
|
WO2018026953A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
MA46236A
(fr)
*
|
2016-09-14 |
2019-07-24 |
Janssen Biotech Inc |
Récepteurs antigéniques chimériques comprenant des domaines de la fibronectine de type iii spécifiques du bcma, et utilisations correspondantes
|
|
IL302917A
(en)
|
2016-10-07 |
2023-07-01 |
Tcr2 Therapeutics Inc |
Compositions and methods for t-cell receptors reprogramming using fusion proteins
|
|
US11124577B2
(en)
|
2016-11-02 |
2021-09-21 |
Engmab Sàrl |
Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
|
|
CN108004259B
(zh)
*
|
2016-11-02 |
2020-06-30 |
上海恒润达生生物科技有限公司 |
靶向b细胞成熟抗原的嵌合抗原受体及其用途
|
|
KR20240005168A
(ko)
|
2016-11-04 |
2024-01-11 |
2세븐티 바이오, 인코포레이티드 |
항-bcma car t 세포 조성물
|
|
JP7291396B2
(ja)
|
2016-11-22 |
2023-06-15 |
ティーシーアール2 セラピューティクス インク. |
融合タンパク質を用いたtcrの再プログラミングのための組成物及び方法
|
|
CN110114070A
(zh)
|
2016-11-23 |
2019-08-09 |
诺华公司 |
使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
|
|
CA3040533A1
(en)
*
|
2016-12-02 |
2018-06-07 |
Cartesian Therapeutics, Inc. |
Cancer immunotherapy with highly enriched cd8+ chimeric antigen receptor t cells
|
|
CN110291200B
(zh)
|
2016-12-12 |
2024-05-14 |
西雅图儿童医院(Dba西雅图儿童研究所) |
对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体
|
|
IL267485B2
(en)
|
2016-12-21 |
2024-01-01 |
Teneobio Inc |
Anti-bcma heavy chain-only antibodies and uses thereof
|
|
CN110475857B
(zh)
*
|
2017-01-05 |
2023-07-18 |
韩国生命工学研究院 |
表达抗-可替宁嵌合抗原受体的天然杀伤细胞
|
|
WO2018144535A1
(en)
|
2017-01-31 |
2018-08-09 |
Novartis Ag |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
|
EP3579870A4
(en)
|
2017-02-07 |
2020-12-30 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS
|
|
SG11201907580SA
(en)
*
|
2017-02-17 |
2019-09-27 |
Hutchinson Fred Cancer Res |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
|
WO2018160622A1
(en)
|
2017-02-28 |
2018-09-07 |
Endocyte, Inc. |
Compositions and methods for car t cell therapy
|
|
MX2019011324A
(es)
|
2017-03-23 |
2020-01-21 |
Massachusetts Gen Hospital |
Bloqueo de cxcr4/cxcr7 y tratamiento de enfermedad asociada con el virus del papiloma humano.
|
|
JP7618192B2
(ja)
*
|
2017-03-28 |
2025-01-21 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
移植された組織を拒絶反応から保護するための方法
|
|
JP7249287B2
(ja)
|
2017-03-31 |
2023-03-30 |
ザ・ボード・オブ・トラスティーズ・オブ・ザ・リーランド・スタンフォード・ジュニア・ユニバーシティ |
T細胞受容体シグナル伝達を阻害または調節することによって、t細胞枯渇を処置する方法
|
|
CN110753555A
(zh)
|
2017-04-19 |
2020-02-04 |
得克萨斯州大学系统董事会 |
表达工程化抗原受体的免疫细胞
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
WO2018201051A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
CA3061945A1
(en)
|
2017-05-01 |
2018-11-08 |
Juno Therapeutics, Inc. |
Combination of a cell therapy and an immunomodulatory compound
|
|
US12226479B2
(en)
|
2017-05-11 |
2025-02-18 |
The General Hospital Corporation |
Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
MY201573A
(en)
|
2017-05-12 |
2024-03-02 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
EP3638218A4
(en)
|
2017-06-14 |
2021-06-09 |
The Broad Institute, Inc. |
COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH
|
|
KR20250007003A
(ko)
|
2017-06-20 |
2025-01-13 |
테네오바이오, 인코포레이티드 |
항-bcma 중쇄-단독 항체
|
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
|
AU2018291128B2
(en)
*
|
2017-06-30 |
2024-10-10 |
Teneobio, Inc. |
Anti-B-cell maturation antigen chimeric antigen receptors with human domains
|
|
US12049643B2
(en)
|
2017-07-14 |
2024-07-30 |
The Broad Institute, Inc. |
Methods and compositions for modulating cytotoxic lymphocyte activity
|
|
WO2019025983A1
(en)
*
|
2017-08-01 |
2019-02-07 |
Medimmune, Llc |
CONJUGATED MONOCLONAL ANTIBODY-MEDICINE DIRECTED AGAINST BCMA
|
|
CN111107874A
(zh)
|
2017-09-14 |
2020-05-05 |
葛兰素史密斯克莱知识产权发展有限公司 |
用于癌症的组合治疗
|
|
WO2019053613A2
(en)
|
2017-09-14 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
POLY THERAPY FOR THE TREATMENT OF CANCER
|
|
WO2019053611A1
(en)
|
2017-09-14 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
POLY THERAPY FOR THE TREATMENT OF CANCER
|
|
JP7654240B2
(ja)
|
2017-09-19 |
2025-04-01 |
マサチューセッツ インスティテュート オブ テクノロジー |
キメラ抗原受容体t細胞治療のための組成物およびその使用
|
|
WO2019070755A1
(en)
|
2017-10-02 |
2019-04-11 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
|
|
WO2019075055A1
(en)
|
2017-10-11 |
2019-04-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
METHODS FOR PRODUCING T-CELL POPULATIONS USING P38 MAPK INHIBITORS
|
|
BR112020007576A2
(pt)
|
2017-10-18 |
2020-09-24 |
Novartis Ag |
composições e métodos para degradação de proteína seletiva
|
|
BR112020008638A2
(pt)
|
2017-11-01 |
2020-10-20 |
Juno Therapeutics Inc |
receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma)
|
|
WO2019089982A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
|
CA3080904A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
|
CN109748968B
(zh)
*
|
2017-11-03 |
2020-12-01 |
西安宇繁生物科技有限责任公司 |
Bcma特异性嵌合抗原受体t细胞及其应用
|
|
AU2018359907A1
(en)
|
2017-11-06 |
2020-05-07 |
Fred Hutchinson Cancer Center |
Combination of a cell therapy and a gamma secretase inhibitor
|
|
WO2019094983A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
|
WO2019094955A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
|
|
AU2018369639C1
(en)
*
|
2017-11-14 |
2025-04-03 |
Arcellx, Inc. |
D-domain containing polypeptides and uses thereof
|
|
US20200360431A1
(en)
|
2017-11-15 |
2020-11-19 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
|
|
EP3714041A1
(en)
|
2017-11-22 |
2020-09-30 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
|
TW201925782A
(zh)
|
2017-11-30 |
2019-07-01 |
瑞士商諾華公司 |
靶向bcma之嵌合抗原受體及其用途
|
|
KR20250010750A
(ko)
*
|
2017-12-20 |
2025-01-21 |
포세이다 테라퓨틱스, 인크. |
Vcar 조성물 및 사용 방법
|
|
CN109971715A
(zh)
*
|
2017-12-28 |
2019-07-05 |
深圳华大生命科学研究院 |
一种扩增特异性car-t细胞的培养方法
|
|
CN109971716B
(zh)
*
|
2017-12-28 |
2023-08-01 |
上海细胞治疗研究院 |
自分泌cd47抗体的egfr特异性car-t细胞及其用途
|
|
TW201930591A
(zh)
|
2018-01-08 |
2019-08-01 |
瑞士商諾華公司 |
用於與嵌合抗原受體療法併用之免疫增強rna
|
|
AU2019209432A1
(en)
|
2018-01-22 |
2020-08-06 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Methods of use for CAR T cells
|
|
CA3090249A1
(en)
|
2018-01-31 |
2019-08-08 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
CA3074526C
(en)
*
|
2018-02-01 |
2021-08-03 |
Nanjing Iaso Biotherapeutics Co., Ltd. |
Chimeric antigen receptor (car) binding to bcma and application thereof
|
|
US11266690B2
(en)
*
|
2018-02-01 |
2022-03-08 |
Nanjing Iaso Biotherapeutics Co., Ltd. |
Chimeric antigen receptor (CAR) binding to BCMA, and uses thereof
|
|
CN111936518A
(zh)
|
2018-02-06 |
2020-11-13 |
西雅图儿童医院(Dba西雅图儿童研究所) |
对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
|
|
WO2019157130A1
(en)
|
2018-02-09 |
2019-08-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Tethered interleukin-15 and interleukin-21
|
|
CN110157675B
(zh)
*
|
2018-02-12 |
2022-05-27 |
深圳宾德生物技术有限公司 |
一种靶向性t淋巴细胞及其制备方法和应用
|
|
WO2019157516A1
(en)
|
2018-02-12 |
2019-08-15 |
resTORbio, Inc. |
Combination therapies
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
EP3755349A4
(en)
|
2018-02-21 |
2021-11-17 |
Board of Regents, The University of Texas System |
PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
|
|
WO2019165237A1
(en)
|
2018-02-23 |
2019-08-29 |
Endocyte, Inc. |
Sequencing method for car t cell therapy
|
|
CN116836297A
(zh)
*
|
2018-04-12 |
2023-10-03 |
上海赛比曼生物科技有限公司 |
靶向bcma的嵌合抗原受体及其制法和应用
|
|
WO2019209715A1
(en)
|
2018-04-24 |
2019-10-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing t cell populations using hydroxycitric acid and/or a salt thereof
|
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
|
JP7542441B2
(ja)
|
2018-05-11 |
2024-08-30 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
癌を治療するための方法及び組成物
|
|
TWI848951B
(zh)
|
2018-06-01 |
2024-07-21 |
瑞士商諾華公司 |
針對bcma之結合分子及其用途
|
|
US20210371932A1
(en)
|
2018-06-01 |
2021-12-02 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
|
CN112566643A
(zh)
|
2018-06-12 |
2021-03-26 |
加利福尼亚大学董事会 |
用于治疗癌症的单链双特异性嵌合抗原受体
|
|
AU2019284911A1
(en)
|
2018-06-13 |
2020-12-17 |
Novartis Ag |
BCMA chimeric antigen receptors and uses thereof
|
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
JP2021530217A
(ja)
*
|
2018-07-10 |
2021-11-11 |
プレシゲン,インコーポレイテッド |
Ror−1特異的キメラ抗原受容体およびその使用
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAx抗-CD3抗體及其用途
|
|
US20210221903A1
(en)
*
|
2018-08-14 |
2021-07-22 |
Hrain Biotechnology Co., Ltd. |
Bcma-targeting chimeric antigen receptor and uses thereof
|
|
ES3042082T3
(en)
|
2018-08-31 |
2025-11-18 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2020047449A2
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP3856775B9
(en)
|
2018-09-27 |
2025-01-22 |
Autolus Limited |
Chimeric antigen receptor
|
|
AU2019346335B2
(en)
|
2018-09-28 |
2024-07-25 |
Massachusetts Institute Of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
|
US20200190163A1
(en)
*
|
2018-10-26 |
2020-06-18 |
Lijun Wu |
Humanized bcma-car-t cells
|
|
WO2020092455A2
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
|
CN112955748A
(zh)
|
2018-10-31 |
2021-06-11 |
葛兰素史密斯克莱知识产权发展有限公司 |
治疗癌症的方法
|
|
AU2019374103A1
(en)
|
2018-11-01 |
2021-05-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)
|
|
AU2019372331A1
(en)
|
2018-11-01 |
2021-05-27 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
|
|
MX2021005366A
(es)
|
2018-11-08 |
2021-09-10 |
Juno Therapeutics Inc |
Metodos y combinaciones para el tratamiento y modulacion de celulas t.
|
|
IL283734B2
(en)
|
2018-12-12 |
2025-03-01 |
Kite Pharma Inc |
Chimeric antigen receptors and CAR-T cells and methods of use
|
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
CA3123167A1
(en)
*
|
2018-12-20 |
2020-06-25 |
Oslo Universitetssykehus Hf |
Chimeric antigen receptors (cars) and their use in medicine
|
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
|
PT3749338T
(pt)
|
2019-01-16 |
2024-09-20 |
Caribou Biosciences Inc |
Anticorpo de bcma humanizado e células bcma-car-t
|
|
AU2020221324A1
(en)
|
2019-02-15 |
2021-09-02 |
University Of Southern California |
Lym-1 and Lym-2 antibody compositions and improved CAR constructs
|
|
KR20210134339A
(ko)
|
2019-02-25 |
2021-11-09 |
노파르티스 아게 |
바이러스 전달을 위한 메조다공성 실리카 입자 조성물
|
|
MX2021010288A
(es)
|
2019-03-01 |
2021-09-23 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes de tumores a partir de tumores liquidos y usos terapeuticos de los mismos.
|
|
EP3773918A4
(en)
|
2019-03-05 |
2022-01-05 |
Nkarta, Inc. |
ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY
|
|
EP3935151A1
(en)
|
2019-03-08 |
2022-01-12 |
Klinikum der Universität München |
Ccr8 expressing lymphocytes for targeted tumor therapy
|
|
WO2020186101A1
(en)
|
2019-03-12 |
2020-09-17 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
CA3158025C
(en)
*
|
2019-03-15 |
2023-07-11 |
Yi Zhang |
Anti-bcma chimeric antigen receptors
|
|
EP3942023A1
(en)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
|
WO2020191316A1
(en)
|
2019-03-21 |
2020-09-24 |
Novartis Ag |
Car-t cell therapies with enhanced efficacy
|
|
CN113646426B
(zh)
|
2019-04-04 |
2024-09-13 |
上海医药集团股份有限公司 |
一种包含肿瘤抗原识别受体的免疫细胞及其应用
|
|
WO2020210678A1
(en)
|
2019-04-12 |
2020-10-15 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
MX2021012740A
(es)
|
2019-04-17 |
2022-01-24 |
Aadigen Llc |
Péptidos y nanopartículas para entrega intracelular de moléculas.
|
|
US20220251152A1
(en)
|
2019-04-24 |
2022-08-11 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
EP3733707A1
(en)
|
2019-04-30 |
2020-11-04 |
Celyad S.A. |
Car t-cells targeting bcma and uses thereof
|
|
US20220249558A1
(en)
|
2019-04-30 |
2022-08-11 |
Crispr Therapeutics Ag |
Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
|
|
SG11202112382WA
(en)
|
2019-05-07 |
2021-12-30 |
Gracell Biotechnologies Shanghai Co Ltd |
Engineered immune cell targeting bcma and use thereof
|
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
|
BR112021023048A2
(pt)
|
2019-05-21 |
2022-04-19 |
Novartis Ag |
Moléculas de ligação a cd19 e usos das mesmas
|
|
EP3990491A1
(en)
|
2019-06-26 |
2022-05-04 |
Massachusetts Institute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
BR112022001546A2
(pt)
|
2019-07-30 |
2022-03-22 |
Jiangsu Hansoh Pharmaceutical Group Co Ltd |
Anticorpo anti-bcma, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo
|
|
NZ784975A
(en)
|
2019-08-06 |
2025-10-31 |
Glaxosmithkline Ip Dev Ltd |
Biopharmacuetical compositions and related methods
|
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
|
US12421557B2
(en)
|
2019-08-16 |
2025-09-23 |
The Broad Institute, Inc. |
Methods for predicting outcomes and treating colorectal cancer using a cell atlas
|
|
KR20220041934A
(ko)
|
2019-08-16 |
2022-04-01 |
얀센 바이오테크 인코포레이티드 |
개선된 기능을 갖는 치료용 면역 세포 및 이의 제조 방법
|
|
CN112409482B
(zh)
*
|
2019-08-20 |
2022-08-26 |
杭州尚健生物技术有限公司 |
Bcma抗体
|
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
EP4031577A4
(en)
*
|
2019-09-18 |
2023-12-20 |
Board of Regents, The University of Texas System |
METHOD FOR CULTURING NATURAL KILLER CELLS AGAINST BCMA-POSITIVE TUMORS
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
US12297426B2
(en)
|
2019-10-01 |
2025-05-13 |
The Broad Institute, Inc. |
DNA damage response signature guided rational design of CRISPR-based systems and therapies
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
US12195725B2
(en)
|
2019-10-03 |
2025-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
|
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
|
CN110642953B
(zh)
*
|
2019-10-12 |
2021-09-17 |
华夏源(上海)细胞基因工程股份有限公司 |
一种靶向bcma的t细胞受体融合蛋白和应用
|
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
|
CA3163104A1
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Chimeric antigen receptors and uses thereof
|
|
WO2021132746A1
(en)
*
|
2019-12-24 |
2021-07-01 |
Abl Bio, Inc. |
Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof
|
|
US20230028399A1
(en)
*
|
2020-01-13 |
2023-01-26 |
Nkarta, Inc. |
Bcma-directed cellular immunotherapy compositions and methods
|
|
US12165747B2
(en)
|
2020-01-23 |
2024-12-10 |
The Broad Institute, Inc. |
Molecular spatial mapping of metastatic tumor microenvironment
|
|
US20230256017A1
(en)
|
2020-02-27 |
2023-08-17 |
Jennifer Brogdon |
Methods of making chimeric antigen receptor-expressing cells
|
|
BR112022016633A2
(pt)
|
2020-02-27 |
2022-12-13 |
Novartis Ag |
Métodos para produzir células que expressam receptor de antígeno quimérico
|
|
JP2023517889A
(ja)
|
2020-03-10 |
2023-04-27 |
マサチューセッツ インスティテュート オブ テクノロジー |
NPM1c陽性がんの免疫療法のための組成物および方法
|
|
CA3173527A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
Methods for generating engineered memory-like nk cells and compositions thereof
|
|
KR102371151B1
(ko)
|
2020-03-13 |
2022-03-07 |
주식회사 큐로셀 |
항-bcma 결합 영역, 이를 포함하는 융합단백질, 및 이를 포함하는 조성물
|
|
EP4142723A2
(en)
|
2020-04-28 |
2023-03-08 |
Juno Therapeutics, Inc. |
Combination of bcma-directed t cell therapy and an immunomodulatory compound
|
|
US12433954B2
(en)
|
2020-05-01 |
2025-10-07 |
Massachusetts Institute Of Technology |
Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
|
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
KR102400977B1
(ko)
|
2020-05-29 |
2022-05-25 |
성균관대학교산학협력단 |
프로세서를 통한 페이지 폴트 처리 방법
|
|
US20230332104A1
(en)
|
2020-06-11 |
2023-10-19 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
EP4192875A1
(en)
*
|
2020-08-10 |
2023-06-14 |
Precision BioSciences, Inc. |
Antibodies and fragments specific for b-cell maturation antigen and uses thereof
|
|
US20230302155A1
(en)
|
2020-08-21 |
2023-09-28 |
Novartis Ag |
Compositions and methods for in vivo generation of car expressing cells
|
|
EP4211228B1
(en)
|
2020-09-08 |
2025-11-05 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
T cell phenotypes associated with response to adoptive cell therapy
|
|
WO2022078344A1
(zh)
|
2020-10-12 |
2022-04-21 |
南京驯鹿医疗技术有限公司 |
一种结合cd70的抗体、嵌合抗原受体(car)及其应用
|
|
US20240002505A1
(en)
|
2020-11-01 |
2024-01-04 |
Nanjing IASO Biotechnology Co., Ltd. |
Fully human antibody targeting cd5, and fully human chimeric antigen receptor (car) and application thereof
|
|
EP4243937A2
(en)
|
2020-11-13 |
2023-09-20 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
|
|
WO2022116952A1
(zh)
|
2020-12-01 |
2022-06-09 |
苏州克睿基因生物科技有限公司 |
靶向cd70的抗原结合蛋白及其应用
|
|
CA3201008A1
(en)
*
|
2020-12-02 |
2022-06-09 |
Shanghai Cellular Biopharmaceutical Group Ltd. |
Bcma-targeted chimeric antigen receptors
|
|
EP4263600A1
(en)
|
2020-12-18 |
2023-10-25 |
Century Therapeutics, Inc. |
Chimeric antigen receptor systems with adaptable receptor specificity
|
|
WO2022147481A1
(en)
|
2020-12-30 |
2022-07-07 |
Ansun Biopharma Inc. |
Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
|
|
CN112321713B
(zh)
*
|
2020-12-31 |
2021-05-25 |
北京艺妙神州医药科技有限公司 |
一种抗bcma的抗体及其应用
|
|
US20240050568A1
(en)
|
2021-01-12 |
2024-02-15 |
Nanjing IASO Biotechnology Co., Ltd. |
Fully human single-domain tandem chimeric antigen receptor (car) targeting cd5, and use thereof
|
|
US20240108654A1
(en)
|
2021-03-03 |
2024-04-04 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and a dgk inhibitor
|
|
IL307612A
(en)
|
2021-04-16 |
2023-12-01 |
Celgene Corp |
Combined therapies with BCMA-directed T-cell therapy
|
|
AU2022257093A1
(en)
|
2021-04-16 |
2023-11-02 |
Celgene Corporation |
T cell therapy in patients who have had prior stem cell transplant
|
|
CN118056008A
(zh)
|
2021-04-27 |
2024-05-17 |
诺华股份有限公司 |
病毒载体生产系统
|
|
CN117916256A
(zh)
|
2021-05-06 |
2024-04-19 |
朱诺治疗学有限公司 |
用于刺激和转导t细胞的方法
|
|
JP2024521187A
(ja)
|
2021-05-28 |
2024-05-28 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
ガンの治療のための組み合わせ療法
|
|
KR20240040786A
(ko)
|
2021-08-03 |
2024-03-28 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
생물제약 조성물 및 안정한 동위원소 표지 펩티드 맵핑 방법
|
|
EP4384544A1
(en)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
|
EP4384598A1
(en)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
|
WO2023019225A2
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
|
AU2022325232A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified primary cells for allogeneic cell therapy
|
|
EP4387991A1
(en)
|
2021-08-18 |
2024-06-26 |
Julius-Maximilians-Universität Würzburg |
Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
|
|
WO2023021477A1
(en)
|
2021-08-20 |
2023-02-23 |
Novartis Ag |
Methods of making chimeric antigen receptor–expressing cells
|
|
CN117858943A
(zh)
|
2021-08-24 |
2024-04-09 |
赛斯尔擎生物技术(上海)有限公司 |
T细胞产品及其用途
|
|
CN118056012B
(zh)
|
2021-08-24 |
2025-05-30 |
赛斯尔擎生物技术(上海)有限公司 |
一种修饰细胞的方法
|
|
CN118159294A
(zh)
|
2021-10-05 |
2024-06-07 |
葛兰素史密斯克莱知识产权发展有限公司 |
用于治疗癌症的联合疗法
|
|
CN119120424A
(zh)
|
2021-11-02 |
2024-12-13 |
辉大(上海)生物科技有限公司 |
一种CRISPR-Cas12i系统
|
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
MX2024005406A
(es)
|
2021-11-03 |
2024-08-06 |
Janssen Biotech Inc |
Reduccion de corticosteroides en el tratamiento con anticuerpos anti-cd38.
|
|
EP4426339A1
(en)
|
2021-11-03 |
2024-09-11 |
Celgene Corporation |
Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
|
|
US20250108113A1
(en)
|
2021-12-30 |
2025-04-03 |
Tr1X, Inc. |
Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof
|
|
CA3241588A1
(en)
|
2021-12-31 |
2023-07-06 |
Sri Krishna |
T cell therapy with vaccination as a combination immunotherapy against cancer
|
|
CN118591560A
(zh)
|
2022-01-25 |
2024-09-03 |
葛兰素史密斯克莱知识产权发展有限公司 |
癌症的组合疗法
|
|
WO2023147515A1
(en)
|
2022-01-28 |
2023-08-03 |
Juno Therapeutics, Inc. |
Methods of manufacturing cellular compositions
|
|
KR20240155390A
(ko)
|
2022-02-17 |
2024-10-28 |
사나 바이오테크놀로지, 인크. |
조작된 cd47 단백질 및 이의 용도
|
|
US20250297282A1
(en)
|
2022-05-05 |
2025-09-25 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
|
US20250345432A1
(en)
|
2022-05-25 |
2025-11-13 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
|
WO2023230581A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
|
CN119585438A
(zh)
|
2022-05-26 |
2025-03-07 |
再生元制药公司 |
用于维持慢病毒载体的组合物及其用途
|
|
EP4565262A2
(en)
|
2022-08-05 |
2025-06-11 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for gprc5d and bcma
|
|
EP4572772A1
(en)
|
2022-08-17 |
2025-06-25 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
|
JP2025531850A
(ja)
|
2022-09-08 |
2025-09-25 |
ジュノー セラピューティクス インコーポレイテッド |
T細胞療法および継続的または間欠的dgk阻害剤投薬の組合せ
|
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
|
WO2024089639A1
(en)
|
2022-10-26 |
2024-05-02 |
Novartis Ag |
Lentiviral formulations
|
|
WO2024097313A1
(en)
|
2022-11-02 |
2024-05-10 |
Sana Biotechnology, Inc. |
Methods for producing t cell therapy products
|
|
WO2024097905A1
(en)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
|
EP4620974A1
(en)
|
2022-11-15 |
2025-09-24 |
Oricell Therapeutics Co., Ltd. |
Anti-afp/hla02 tcr-like antibody and use thereof
|
|
WO2024121711A1
(en)
|
2022-12-05 |
2024-06-13 |
Glaxosmithkline Intellectual Property Development Limited |
Methods of treatment using b-cell maturation antigen antagonists
|
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
|
CN121100267A
(zh)
|
2022-12-09 |
2025-12-09 |
朱诺治疗学股份有限公司 |
使用全息成像预测细胞表型的机器学习方法
|
|
EP4658675A1
(en)
|
2023-02-03 |
2025-12-10 |
C3S2 GmbH |
Methods for non-viral manufacturing of engineered immune cells
|
|
WO2024168192A1
(en)
|
2023-02-10 |
2024-08-15 |
Celgene Corporation |
Assessment of bcma in biological samples
|
|
CN116535521B
(zh)
*
|
2023-03-08 |
2024-12-24 |
深圳细胞谷生物医药有限公司 |
靶向bcma嵌合抗原受体及其应用
|
|
KR20250131823A
(ko)
|
2023-03-31 |
2025-09-03 |
아벨제타 인크. |
Cd20 및 bcma를 표적화하는 이중특이적 키메라 항원 수용체
|
|
WO2025029930A1
(en)
|
2023-07-31 |
2025-02-06 |
Legend Biotech Ireland Limited |
Cells overexpressing cd31 and methods of use thereof
|
|
WO2025043172A1
(en)
|
2023-08-23 |
2025-02-27 |
Sana Biotechnology, Inc. |
Modified cd47 proteins and their uses
|
|
WO2025059533A1
(en)
|
2023-09-13 |
2025-03-20 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|
|
WO2025137751A1
(pt)
*
|
2023-12-26 |
2025-07-03 |
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein |
Polinucleotídeo, receptor de antígeno quimérico, vetor, composição, método para produção de célula imune efetora modificada e uso do polinucleotídeo
|
|
WO2025160480A1
(en)
|
2024-01-26 |
2025-07-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1
|
|
WO2025250587A1
(en)
|
2024-05-29 |
2025-12-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Drug-regulatable, inducible cytokine expression
|